Minakem-flap
Minakem-flap

Find Gastroenterology Drugs in Phase II Clinical Development in UNITED STATES

Loading...

All Data

Filters Filter refresh
×
FILTER DATA :
News Type filter
    Company filter
      Product Type filter
        Deal Size filter
          Upfront Payment filter
            refresh

            Product Type Full Screen

            Companies Full Screen

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): Latiglutenase

            Therapeutic Area: Gastroenterology Product Name: IMGX003

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: National Institutes of Health

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 18, 2021

            Details:

            CeliacShield Trial is a double-blind, placebo controlled, gluten challenge trial of the efficacy, safety and tolerability of 6-weeks treatment of Latiglutenase (IMGX003) administration in patients with well-controlled celiac disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): OPL-002

            Therapeutic Area: Gastroenterology Product Name: OPL-002

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: venBio

            Deal Size: $114.0 million Upfront Cash: Undisclosed

            Deal Type: Financing March 09, 2021

            Details:

            OPL-002 is a highly selective and orally bioavailable small molecule S1P modulator in development for ulcerative colitis that was designed to mitigate these limitations.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SER-287

            Therapeutic Area: Gastroenterology Product Name: SER-287

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable March 02, 2021

            Details:

            SER-287, Seres’ second microbiome therapeutic to reach late-stage clinical trials following a successful Phase 3 readout for SER-109, could represent a new therapeutic paradigm for UC by targeting underlying biological drivers of the disease.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): ORP-101

            Therapeutic Area: Gastroenterology Product Name: ORP-101

            Highest Development Status: Phase II Product Type: Small molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 26, 2021

            Details:

            OrphoMed announced that its ORP-101 molecule successfully cleared its first interim futility analysis in a Phase 2 clinical trial for treatment of irritable bowel syndrome with diarrhea (IBS-D).

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): SER-287,Vancomycin Hydrochloride

            Therapeutic Area: Gastroenterology Product Name: SER-287

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable January 06, 2021

            Details:

            The study results demonstrated that SER-287 administration was associated with positive impacts on clinical remission, endoscopic improvement, modulation of the gastrointestinal microbiome, and a favorable tolerability profile.

            Virtual Booth Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

            Contact the Supplier

            Lead Product(s): AMT-101

            Therapeutic Area: Gastroenterology Product Name: AMT-101

            Highest Development Status: Phase II Product Type: Large molecule

            Partner/Sponsor/Collaborator: Not Applicable

            Deal Size: Not Applicable Upfront Cash: Not Applicable

            Deal Type: Not Applicable November 10, 2020

            Details:

            AMT-101 (oral fusion protein of hIL-10 and AMT carrier) rapidly and efficiently transports through intestinal epithelia in healthy and inflamed conditions to target local intestinal tissue.